Drug intelligence / Profile preview

Diabec

Development stage: Unknown
Lead developer: Alfa Intes
Modality: Small Molecules
Administration: Oral

Overview

Diabec is a multi-ingredient nutraceutical developed by Alfa Intes, specifically formulated to support retinal health in patients with inflammatory eye conditions. Its primary component is curcumin, delivered via the hydrophilic CurcuWIN carrier to enhance bioavailability. The formulation also includes Coenzyme Q10, lutein, docosahexaenoic acid (DHA), vitamins C and E, and trace elements including zinc, copper, and selenium. Diabec acts as an adjuvant to standard pharmacological treatments for diabetic retinopathy and diabetic macular edema by inhibiting the synthesis of inflammatory mediators and providing antioxidant protection to the retinal tissues. Clinical studies have demonstrated its efficacy when combined with standard treatments for diabetic macular edema and non-infectious uveitis.

Brand names: Diabec

Beyond the preview

Go deeper on Diabec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabec.

Explore the full profile